496 related articles for article (PubMed ID: 26748828)
1. Targeting BRCA1 and BRCA2 Deficiencies with G-Quadruplex-Interacting Compounds.
Zimmer J; Tacconi EMC; Folio C; Badie S; Porru M; Klare K; Tumiati M; Markkanen E; Halder S; Ryan A; Jackson SP; Ramadan K; Kuznetsov SG; Biroccio A; Sale JE; Tarsounas M
Mol Cell; 2016 Feb; 61(3):449-460. PubMed ID: 26748828
[TBL] [Abstract][Full Text] [Related]
2. Anti-tumoural activity of the G-quadruplex ligand pyridostatin against BRCA1/2-deficient tumours.
Groelly FJ; Porru M; Zimmer J; Benainous H; De Visser Y; Kosova AA; Di Vito S; Serra V; Ryan A; Leonetti C; Bruna A; Biroccio A; Tarsounas M
EMBO Mol Med; 2022 Mar; 14(3):e14501. PubMed ID: 35107878
[TBL] [Abstract][Full Text] [Related]
3. Shieldin complex promotes DNA end-joining and counters homologous recombination in BRCA1-null cells.
Dev H; Chiang TW; Lescale C; de Krijger I; Martin AG; Pilger D; Coates J; Sczaniecka-Clift M; Wei W; Ostermaier M; Herzog M; Lam J; Shea A; Demir M; Wu Q; Yang F; Fu B; Lai Z; Balmus G; Belotserkovskaya R; Serra V; O'Connor MJ; Bruna A; Beli P; Pellegrini L; Caldas C; Deriano L; Jacobs JJL; Galanty Y; Jackson SP
Nat Cell Biol; 2018 Aug; 20(8):954-965. PubMed ID: 30022119
[TBL] [Abstract][Full Text] [Related]
4. REV7 counteracts DNA double-strand break resection and affects PARP inhibition.
Xu G; Chapman JR; Brandsma I; Yuan J; Mistrik M; Bouwman P; Bartkova J; Gogola E; Warmerdam D; Barazas M; Jaspers JE; Watanabe K; Pieterse M; Kersbergen A; Sol W; Celie PHN; Schouten PC; van den Broek B; Salman A; Nieuwland M; de Rink I; de Ronde J; Jalink K; Boulton SJ; Chen J; van Gent DC; Bartek J; Jonkers J; Borst P; Rottenberg S
Nature; 2015 May; 521(7553):541-544. PubMed ID: 25799992
[TBL] [Abstract][Full Text] [Related]
5. G-quadruplex DNA as a molecular target for induced synthetic lethality in cancer cells.
McLuckie KI; Di Antonio M; Zecchini H; Xian J; Caldas C; Krippendorff BF; Tannahill D; Lowe C; Balasubramanian S
J Am Chem Soc; 2013 Jul; 135(26):9640-3. PubMed ID: 23782415
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment.
Oplustilova L; Wolanin K; Mistrik M; Korinkova G; Simkova D; Bouchal J; Lenobel R; Bartkova J; Lau A; O'Connor MJ; Lukas J; Bartek J
Cell Cycle; 2012 Oct; 11(20):3837-50. PubMed ID: 22983061
[TBL] [Abstract][Full Text] [Related]
7. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.
Yuan B; Ye N; Song SS; Wang YT; Song Z; Chen HD; Chen CH; Huan XJ; Wang YQ; Su Y; Shen YY; Sun YM; Yang XY; Chen Y; Guo SY; Gan Y; Gao ZW; Chen XY; Ding J; He JX; Zhang A; Miao ZH
Cancer Lett; 2017 Feb; 386():47-56. PubMed ID: 27847302
[TBL] [Abstract][Full Text] [Related]
8. Phosphoglycerate mutase 1 regulates dNTP pool and promotes homologous recombination repair in cancer cells.
Qu J; Sun W; Zhong J; Lv H; Zhu M; Xu J; Jin N; Xie Z; Tan M; Lin SH; Geng M; Ding J; Huang M
J Cell Biol; 2017 Feb; 216(2):409-424. PubMed ID: 28122957
[TBL] [Abstract][Full Text] [Related]
9. DNA repair and cell cycle checkpoint defects in a mouse model of 'BRCAness' are partially rescued by 53BP1 deletion.
Misenko SM; Patel DS; Her J; Bunting SF
Cell Cycle; 2018; 17(7):881-891. PubMed ID: 29620483
[TBL] [Abstract][Full Text] [Related]
10. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase.
Bryant HE; Schultz N; Thomas HD; Parker KM; Flower D; Lopez E; Kyle S; Meuth M; Curtin NJ; Helleday T
Nature; 2005 Apr; 434(7035):913-7. PubMed ID: 15829966
[TBL] [Abstract][Full Text] [Related]
11. Combining 53BP1 with BRCA1 as a biomarker to predict the sensitivity of poly(ADP-ribose) polymerase (PARP) inhibitors.
Yang ZM; Liao XM; Chen Y; Shen YY; Yang XY; Su Y; Sun YM; Gao YL; Ding J; Zhang A; He JX; Miao ZH
Acta Pharmacol Sin; 2017 Jul; 38(7):1038-1047. PubMed ID: 28414200
[TBL] [Abstract][Full Text] [Related]
12. H2AX promotes replication fork degradation and chemosensitivity in BRCA-deficient tumours.
Dibitetto D; Liptay M; Vivalda F; Dogan H; Gogola E; González Fernández M; Duarte A; Schmid JA; Decollogny M; Francica P; Przetocka S; Durant ST; Forment JV; Klebic I; Siffert M; de Bruijn R; Kousholt AN; Marti NA; Dettwiler M; Sørensen CS; Tille JC; Undurraga M; Labidi-Galy I; Lopes M; Sartori AA; Jonkers J; Rottenberg S
Nat Commun; 2024 May; 15(1):4430. PubMed ID: 38789420
[TBL] [Abstract][Full Text] [Related]
13. Premature mitotic entry induced by ATR inhibition potentiates olaparib inhibition-mediated genomic instability, inflammatory signaling, and cytotoxicity in BRCA2-deficient cancer cells.
Schoonen PM; Kok YP; Wierenga E; Bakker B; Foijer F; Spierings DCJ; van Vugt MATM
Mol Oncol; 2019 Nov; 13(11):2422-2440. PubMed ID: 31529615
[TBL] [Abstract][Full Text] [Related]
14. CX-5461 is a DNA G-quadruplex stabilizer with selective lethality in BRCA1/2 deficient tumours.
Xu H; Di Antonio M; McKinney S; Mathew V; Ho B; O'Neil NJ; Santos ND; Silvester J; Wei V; Garcia J; Kabeer F; Lai D; Soriano P; Banáth J; Chiu DS; Yap D; Le DD; Ye FB; Zhang A; Thu K; Soong J; Lin SC; Tsai AH; Osako T; Algara T; Saunders DN; Wong J; Xian J; Bally MB; Brenton JD; Brown GW; Shah SP; Cescon D; Mak TW; Caldas C; Stirling PC; Hieter P; Balasubramanian S; Aparicio S
Nat Commun; 2017 Feb; 8():14432. PubMed ID: 28211448
[TBL] [Abstract][Full Text] [Related]
15. Discovery of MTR-106 as a highly potent G-quadruplex stabilizer for treating BRCA-deficient cancers.
Li MZ; Meng T; Song SS; Bao XB; Ma LP; Zhang N; Yu T; Zhang YL; Xiong B; Shen JK; Miao ZH; He JX
Invest New Drugs; 2021 Oct; 39(5):1213-1221. PubMed ID: 33710464
[TBL] [Abstract][Full Text] [Related]
16. Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations.
Dedes KJ; Wilkerson PM; Wetterskog D; Weigelt B; Ashworth A; Reis-Filho JS
Cell Cycle; 2011 Apr; 10(8):1192-9. PubMed ID: 21487248
[TBL] [Abstract][Full Text] [Related]
17. Radiosensitivity Is an Acquired Vulnerability of PARPi-Resistant BRCA1-Deficient Tumors.
Barazas M; Gasparini A; Huang Y; Küçükosmanoğlu A; Annunziato S; Bouwman P; Sol W; Kersbergen A; Proost N; de Korte-Grimmerink R; van de Ven M; Jonkers J; Borst GR; Rottenberg S
Cancer Res; 2019 Feb; 79(3):452-460. PubMed ID: 30530501
[TBL] [Abstract][Full Text] [Related]
18. Cockayne syndrome group B protein regulates fork restart, fork progression and MRE11-dependent fork degradation in BRCA1/2-deficient cells.
Batenburg NL; Mersaoui SY; Walker JR; Coulombe Y; Hammond-Martel I; Wurtele H; Masson JY; Zhu XD
Nucleic Acids Res; 2021 Dec; 49(22):12836-12854. PubMed ID: 34871413
[TBL] [Abstract][Full Text] [Related]
19. The G-quadruplex DNA stabilizing drug pyridostatin promotes DNA damage and downregulates transcription of Brca1 in neurons.
Moruno-Manchon JF; Koellhoffer EC; Gopakumar J; Hambarde S; Kim N; McCullough LD; Tsvetkov AS
Aging (Albany NY); 2017 Sep; 9(9):1957-1970. PubMed ID: 28904242
[TBL] [Abstract][Full Text] [Related]
20. RADX Promotes Genome Stability and Modulates Chemosensitivity by Regulating RAD51 at Replication Forks.
Dungrawala H; Bhat KP; Le Meur R; Chazin WJ; Ding X; Sharan SK; Wessel SR; Sathe AA; Zhao R; Cortez D
Mol Cell; 2017 Aug; 67(3):374-386.e5. PubMed ID: 28735897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]